Latest news with #AspireBiopharma
Yahoo
7 days ago
- Business
- Yahoo
Aspire Biopharma provides development update on BUZZ BOMB supplement
Aspire Biopharma (ASBP) announced the brand name BUZZ BOMB and anticipated market launch for its novel sublingual pre-workout supplement. BUZZ BOMB features 50mg of caffeine and is designed to support sustained energy and mental focus, helping athletes and fitness enthusiasts maximize their performance potential. Aspire has commenced initial production of BUZZ BOMB, its single serving pre-workout caffeine supplement utilizing Aspire's patent-pending and proprietary sublingual delivery pre-workout formula is conveniently packaged in a single serving packet for easy on-the-go use. Consumers will have a choice of six BUZZ BOMB flavors, including Tropical Fruit, Mixed Berry, Watermelon, Lemon Lime, Peach Mango, and Mocha Coffee. The Company expects to begin expanded pre-launch consumer testing of this supplement product during the second quarter of 2025. In August, the Company will have a booth and be an event sponsor at two of the largest fitness conferences in the nation where over 50,000 people interested in health, fitness, optimization, nutrition, and overall wellbeing will be able to taste, sample, and experience the BUZZ BOMB pre-workout supplement. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on ASBP: Disclaimer & DisclosureReport an Issue Aspire announces first patient dosed in Phase 1 trial of aspirin formulation Aspire Biopharma files to sell 8.33M shares of common stock for holders Aspire announces IRB approval for in-human trial of aspirin formulation Aspire commences initial production of pre-workout performance supplement Aspire announces Phase 1 trial initiation of high-dose aspirin formulation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
28-05-2025
- Business
- Globe and Mail
Pharma Stock Massively Bid Up Following New Product Announcement
A Pharmaceuticals company based out of Puerto Rico is turning heads so far during Wednesday's premarket hours after the company introduced its new 'BUZZ BOMB' pre-workout supplement and announced it expects to launch in Q3. Traders wasted no time buying up shares of Aspire Biopharma Holdings Inc. (Nasdaq:ASBP), with shares of the micro cap currently bid up at $.4001/share (+77.82%) leading up to the opening bell. It should be an exciting session for this stock! Aspire Biopharma is developing next generation absorption of medicine that will have a significant impact on the opioid crisis. Our nano technology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tract. Aspire's technology comes from a new mechanism of action (absorption pathway) which allows for instant absorption in the mouth. Benefits of "instant absorption" are to provide nearly instant treatment impact and also allows high dose absorption. Our technology can be applied to any number of proven drugs and supplements, such as analgesics, erectile dysfunction, and traumatic brain injury drugs. Copyright © 2025 All rights reserved. Republication or redistribution of content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. View more of this article on About Media, Inc.: Founded in 1999, is one of North America's leading platforms for micro-cap insights. Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders. is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals. Want to showcase your company's story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today. Contact: Media, Inc.
Yahoo
11-03-2025
- Business
- Yahoo
An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation
SmallCaps Daily Dives Deep with CEO Kraig Higginson to Discuss Aspire's Mission to Enhance Efficacy and Reduce Side Effects New York, New York--(Newsfile Corp. - March 11, 2025) - Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) ("Aspire" or the "Company") is revolutionizing drug delivery through its proprietary sublingual technology, designed to rapidly deliver therapeutics while bypassing the gastrointestinal tract and liver. SmallCaps Daily sat down with CEO Kraig Higginson to learn more about Aspire's mission to enhance existing drugs-from fast-acting aspirin and ED treatments to hormonal therapies and supplements-while reducing side effects and improving patient outcomes. With multiple product launches expected this year and a focus on strategic licensing partnerships with major pharmaceutical players, Aspire Biopharma is positioning itself at the forefront of a $100 billion industry primed for innovation. To read the full article, visit: About Aspire Biopharma, in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit Contact InformationSmallCapsDailyinfo@ To view the source version of this press release, please visit
Associated Press
11-03-2025
- Business
- Associated Press
An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation
SmallCaps Daily Dives Deep with CEO Kraig Higginson to Discuss Aspire's Mission to Enhance Efficacy and Reduce Side Effects New York, New York--(Newsfile Corp. - March 11, 2025) - Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) ('Aspire' or the 'Company') is revolutionizing drug delivery through its proprietary sublingual technology, designed to rapidly deliver therapeutics while bypassing the gastrointestinal tract and liver. SmallCaps Daily sat down with CEO Kraig Higginson to learn more about Aspire's mission to enhance existing drugs-from fast-acting aspirin and ED treatments to hormonal therapies and supplements-while reducing side effects and improving patient outcomes. With multiple product launches expected this year and a focus on strategic licensing partnerships with major pharmaceutical players, Aspire Biopharma is positioning itself at the forefront of a $100 billion industry primed for innovation. To read the full article, visit: About Aspire Biopharma, Inc. Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time.
Yahoo
21-02-2025
- Business
- Yahoo
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement
NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology (Nasdaq:ASBP)(Nasdaq:ASBPW), today announced that it entered into a definitive Securities Purchase Agreement (the "Agreement") on February 19, 2025, pursuant to which the Company issued to the Buyers a senior secured convertible debenture (the "Debenture"). The Debenture is only convertible in the event of a default or at the Company's discretion. The closing of the transaction is expected to occur on February 20, 2025 (the "Closing Date"). The transaction will result in gross proceeds to the Company of $3.0 million. Proceeds from the transaction will support the Company's general working capital and operating expenses. Kraig Higginson, Chief Executive Officer of Aspire, commented, "This senior secured convertible debenture was structured to avoid any inclusion of warrants or resets often associated with DESPAC transactions. In addition, the investors in the debenture transaction, have agreed to a volume restriction prohibiting each of them from selling more than 15% of the daily volume. We are pleased to have concluded this transaction which strengthens the Company's capital structure and improves its near- term liquidity position, enhancing our ability to continue the development of innovative and improved formulations of approved FDA drugs and nutraceuticals while maximizing long term shareholder value." Dawson James Securities, Inc. and RBW Capital Partners LLC, a division of Dawson James Securities, Inc. (the "Placement Agent") are acting as exclusive placement agents for the offering. ArentFox Schiff LLP acted as legal counsel to the Placement Agent and Sichenzia Ross Ference Carmel LLP is acted as legal counsel to the Company. About Aspire Biopharma, Inc. Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit Safe Harbor Statement Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Information concerning factors that could cause Aspire's actual results to differ materially from those contained in these forward-looking statements can be found in the Company's Annual Report on Form 10-K, subsequent quarterly reports on Form 10-Q and initial public offering prospectus. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Aspire Biopharma, Inc. Contact TraDigital IRKevin McGrath+1-646-418-7002kevin@ SOURCE: Aspire Biopharma, Inc. View the original press release on ACCESS Newswire
